Anti-C1q Antibody
Guillain-Barré Syndrome (GBS) & other neuroinflammatory diseases
PreclinicalActive
Key Facts
Indication
Guillain-Barré Syndrome (GBS) & other neuroinflammatory diseases
Phase
Preclinical
Status
Active
Company
About Montis Biosciences
Montis Biosciences is a private, preclinical-stage biotech founded in 2021 and based in Leuven, Belgium. The company's core innovation is a platform for discovering dual-mechanism anti-C1q antibodies designed to inhibit the classical complement pathway while also modulating C1q's complement-independent effects on myeloid cells, offering a novel approach in neuroinflammation. With a lead program in Guillain-Barré syndrome and a partnered oncology asset, Montis is backed by a strong syndicate of life science investors including Pfizer Ventures and VIB.
View full company profile